Optimizing Rheumatology Prior Authorization Automation

The High-Volume PA Categories in Rheumatology

Prior authorization in rheumatology is heavily concentrated on high-cost biologics and targeted synthetic DMARDs, which are central to managing chronic autoimmune diseases. These therapies frequently trigger PA requirements due to their expense and the need for stringent clinical oversight, making them a primary focus for automation. This includes treatments for conditions such as RA, PsA, AS, and lupus.

Key PA-Triggering Therapies and Procedures

• TNF-alpha inhibitors (e.g., adalimumab, etanercept, infliximab, certolizumab, golimumab)
• Non-TNF biologics and targeted synthetic DMARDs (e.g., IL-6, IL-17, IL-23 inhibitors, B-cell depletion, JAK inhibitors)
• Specialty drugs for specific indications (e.g., anifrolumab, belimumab, tildrakizumab, ustekinumab)
• Advanced imaging for inflammatory arthritis assessment (e.g., MRI, ultrasound-guided injections)
• DEXA scans for osteoporosis management in chronic-steroid patients

Essential Documentation for Rheumatology PAs

• Diagnosis documentation with disease-specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA, 2019 EULAR/ACR for SLE) [acr-treatment-guidelines]
• Disease activity assessment scores (e.g., DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE)
• Documentation of prior conventional DMARD trial and response (e.g., methotrexate, sulfasalazine) [acr-treatment-guidelines]
• Evidence of step therapy compliance, including biosimilar substitution mandates
• Completion of required screenings (e.g., TB, hepatitis B/C, immunization status) prior to immunosuppressive biologic initiation

Common Denial Reasons in Rheumatology PAs

• Failure to document required step therapy completion or specific prior agent trial
• Denial of brand TNF inhibitor when a biosimilar is mandated for initial trial
• Absence of documented disease activity scores (e.g., DAS28, CDAI, PASI)
• Insufficient duration of conservative care or initial csDMARD trial
• Gaps in screening documentation (e.g., TB, hepatitis, immunization)
• Off-indication use without explicit payer policy support for the requested condition

Klivira's Tailored Approach for Rheumatology Prior Authorization Automation

Klivira’s platform is engineered to address the specific nuances of rheumatology prior authorization. Our system incorporates ACR-guideline-aware policy logic for precise step therapy sequencing and handles the variability of biosimilar substitution mandates across different payers. This targeted functionality streamlines the PA process, reducing administrative burden and improving approval rates.

Klivira's Rheumatology-Specific Capabilities

• ACR-guideline-aware policy logic for indication-specific step therapy sequencing [acr-treatment-guidelines]
• Dynamic biosimilar substitution routing that adapts to per-payer mandates and brand-to-biosimilar conversion workflows
• Automated periodic re-authorization workflows for chronic biologic treatments, ensuring continuous response documentation
• Intelligent medical-vs-pharmacy benefit split routing for the same agent based on administration mode and payer policy
• Specialized pediatric PA flows incorporating weight-based dosing and pediatric guideline criteria